T-CURX is an SME-partner in the EU Innovative Medicines Initiative (IMI) grant "T2EVOLVE" aiming at increasing the access of European cancer patients to innovative CAR-T cell therapies
Today, T-CURX announces that it is an SME-partner (small, medium-sized enterprise) in the € 9.5 M EU Innovative Medicines Initiative (IMI) grant-funded "T2EVOLVE" project.
T2EVOLVE is a new breakthrough alliance of European partners with leading academic institutions and industry partners in the field of immunotherapy. The objective of the T2EVOLVE project is to establish standards for pre-clinical development, manufacturing, and clinical use of CAR-T and TCR-T immunotherapies. The consortium aims to boost Europe to the forefront of immunotherapy. The consortium includes 6 EFPIA companies (European Federation of Pharmaceutical Industries and Associations), 14 European academic institutions, 4 small and medium-sized enterprises, and 3 associated partners or patient organizations.
The strategic objective of the T2EVOLVE Consortium is to accelerate development and to increase awareness and access of cancer patients to CAR-T cell therapies. Simultaneously, T2EVOLVE aims to provide guidance on the sustainable integration of these treatments into the EU healthcare system and help alleviate the financial burden of healthcare on the economy and society.